Cover Image
市場調查報告書

PharmaPoint:HER2陽性乳癌 - 全球醫藥品的預測與市場分析

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 320818
出版日期 內容資訊 英文 323 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:HER2陽性乳癌 - 全球醫藥品的預測與市場分析 PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023
出版日期: 2014年09月30日 內容資訊: 英文 323 Pages
簡介

所謂HER2陽性乳癌,是全球第二大常見癌症,尤其在女性之間最常見。1998年Roche開發單株抗體Herceptin(Trastuzumab)以來,這個疾病的治療方法戲劇性地改變了。由於可以把HER2作為標靶治療,乳癌的無病存活率(DFS)大幅度提高,開拓了HER2標靶治療的市場。現在,Roche也壓倒性佔HER2陽性乳癌治療藥市場的95%。該公司在Herceptin的專利失效後也開發學名藥(Perjeta及Kadcyla)維持市場主導權,預測壟斷體制暫時將保持不變。

本報告提供全球主要7個國家的HER2乳癌治療方法相關最新的研究、開發情形、市場未來展望分析、疾病概要和治療方法、市場機會及未滿足需求、市場規模趨勢(今後10年份)、已上市/臨床實驗中主要的治療藥簡介(功效、安全性、市場競爭力)、全球整體、各國市場的現狀與今後的方向性等資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因與病理學
    • 病因
    • 病理學
  • 基本的胸部解剖學
  • 乳癌的病期分類
  • 預後
  • 生活品質(QoL)
  • 症狀

第4章 流行病學

  • 疾病的背景情況
  • 風險要素和共生病症
    • 如果有乳癌及BRCA1/2遺傳基因突變的家族病史,發病風險大幅度上升
    • 生殖荷爾蒙的因素,影響乳癌風險
    • 可以生活方式改變的要素,影響乳癌患者的死亡風險
    • 檢驗計劃降低了癌症的死亡率,不過,需要仔細比對其優點和風險
  • 全球趨勢
    • 發病率
    • 患者數、生存者數
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 乳癌的流行病學的預測(今後11年份):受診的發病者的病例數
    • 確診的乳癌發病者的數量
    • 確診的乳癌發病者的數量:各年齡
    • 確診的乳癌發病者的數量:閉經的有無
    • 確診的乳癌發病者的數量:診斷時的病期(階段)
    • 確診的乳癌發病者的數量(已調整年齡)
  • 乳癌的流行病學的預測(今後11年份):受診的患病者的病例數
    • 乳癌的5年患病人數(確診)
    • 乳癌的5年患病人數(確診):閉經的有無
    • 乳癌的5年患病人數(確診):荷爾蒙受體的各類型
  • 議論
    • 流行病學預測的考察
    • 分析的限制
    • 分析的優勢

第5章 疾病管理

  • 治療概要
    • 早期階段的乳癌(階段0∼IB)的治療方法
    • 局部進行性及地區的乳癌(病期IB∼IIIA)的治療方法
    • 轉移性HER2-陽性乳癌(病期IV)的治療方法
  • 美國
    • 診斷
    • 臨床診療
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 中國

第6章 競爭評估

  • 概要
  • 產品簡介:HER2標靶治療
    • Herceptin (trastuzumab)
    • Tykerb (lapatinib)
    • Perjeta (pertuzumab)
    • Kadcyla(ado-trastuzumab emtansine, T-DM1)
  • 產品簡介: 一般標靶治療
    • Afinitor (everolimus)
    • Xeloda (capecitabine)
    • Avastin (bevacizumab)
    • Halaven (eribulin mesylate)
    • Abraxane (nab-paclitaxel)
    • Ixempra (ixabepilone)
  • 荷爾蒙劑
    • Tamoxifen
    • Faslodex (fulvestrant)
    • Aromatase 抑制劑

第7章 未滿足需求及機會

  • 概要
  • 腦轉移
    • 未滿足需求
    • 差距分析
    • 機會
  • HER2-對標靶治療的抗性
    • 未滿足需求
    • 差距分析
    • 機會

第8章 開發平台評估

  • 概要
  • 臨床實驗階段的有潛力藥物
    • Gilotrif(afachinibu)
    • Neratinib
  • 臨床實驗早期階段的有潛力藥物
    • Palbociclib
    • NeuVax(nelipepimut-S)
    • Patritumab
    • Ganetespib
    • ARRY-380(ONT-380)
    • NVP-BYL719
  • 生技仿製藥

第9章 現在及未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Roche/Genentech
    • GlaxoSmithKline
    • Boehringer Ingelheim
    • Novartis
    • Pfizer

第10章 市場預測

  • 全球市場
    • 預測
    • 推進因素及障礙 : 全球問題
  • 美國
    • 預測
    • 近幾年的主要趨勢
    • 推進因素及障礙
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 中國

第11章 附錄

圖表一覽

目錄
Product Code: GDHC86PIDR

HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic.

Since its introduction in 1998, Roche's gold standard therapy, Herceptin (trastuzumab), a monoclonal antibody, revolutionized the treatment of the disease. The realization that targeting the HER2 receptor could significantly improve disease-free survival (DFS) has created a large market for HER2-directed therapies. In 2013, Roche dominated the HER2-positive market, with a share of 95%. With Herceptin's patent expiry looming in Europe Roche launched Perjeta and Kadcyla in 2012 and 2013 to maintain its leadership. GlobalData forecasts that the two monoclonal antibodies that also target the HER2 receptor will ensure Roche still occupies over 95% of the market in 2023.

The challenge for new entrants into the HER2-positive market is to find patient populations that are currently underserved, and can work cooperatively with Roche's targeted therapies. The HER2-positive pipeline is weak, and there are still unmet needs that have yet to be suitably addressed. GlobalData expects that the HER2-positive market will grow due to the premium pricing of new agents, and an increasing aging population in the US, 5EU, Japan, and China.

Highlights

Key Questions Answered

  • What are the R&D strategies being used by drug makers?
  • How is the disease management evolving? What impact for drug manufacturers?
  • What opportunities remain for future players?
  • How large are the neoadjuvant, adjuvant, and metastatic markets for HER2 targeting agents, and which one is growing the fastest?
  • What exciting, innovative approaches are being investigated in HER2-positive breast cancer?
  • What to KOLs think about the latest therapies and drug development strategies?

Key Findings

  • The HER2-positive breast cancer market will increase by 2.5-fold, reaching $12.63bn by 2023, at a CAGR of 9.82%, driven by the rapid uptake of the latest premium-priced biologics. Approval of these agents in the early (non-metastatic) stages will have the greatest impact on the market, along with combinations of branded therapies.
  • By 2023, the largest market segment will be the adjuvant setting, with rapid growth at a CAGR of 12.3%, and representing 63% of the total HER2-positive market. Herceptin will no longer be the market leader, with new agents Perjeta and Kadcyla taking 37% and 39% market share respectively.
  • The patent expiry of Herceptin in the 5EU in 2014, and in the US in 2019, will significantly reduce Herceptin sales, however, its introduction of a more convenient subcutaneous reformulation of Herceptin will limit this impact.
  • Development of new HER2-targeting therapies is slow, with only one agent, Puma Biotechnology's neratinib, in Phase III, following the failure of BI's gilotrif. The recent failure of GSK's Tykerb in the adjuvant setting shows that TKIs are best suited to later stages of metastatic disease.
  • Entry into the Roche-dominated HER2-positive market is challenging, with new players needing to find alternative MOAs in underserved patient populations. KOLs identified areas of important unmet need that can still provide opportunities in the HER2-positive space.
  • Future drug development will begin to merge the HER2-positive and HER2-negative populations, as new targets and MOAs are developed, providing exciting opportunities.

Scope

  • Overview of HER2-positive breast cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized HER2-positive breast cancer therapeutics market revenue, annual cost of therapy, and treatment usage patterns in six patient segments (including neoadjuvant and adjuvant), forecast from 2013 to 2023.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the HER2-positive breast cancer therapeutics market
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising candidate in Phase III development is profiled.
  • Analysis of the current and future market competition in the global HER2-positive breast cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global HER2-positive breast cancer therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HER2-positive breast cancer therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Basic Breast Anatomy
  • 3.3. Breast Cancer Staging
  • 3.4. Prognosis
  • 3.5. Quality of Life
  • 3.6. Symptoms

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
    • 4.2.1. A family history of breast cancer and BRCA1/2 gene mutations significantly increase the breast cancer risk
    • 4.2.2. Reproductive hormonal factors influence the risk of breast cancer
    • 4.2.3. Modifiable lifestyle-related factors increase the risk of mortality in breast cancer patients
    • 4.2.4. Screening programs have been shown to reduce breast cancer mortality, although the benefits need to be carefully weighed against the risks
  • 4.3. Global Trends
    • 4.3.1. Incidence
    • 4.3.2. Prevalence and Survival
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast for Breast Cancer (2013-2023) - Diagnosed Incident Cases
    • 4.5.1. Diagnosed Incident Cases of Breast Cancer
    • 4.5.2. Diagnosed Incident Cases of Breast Cancer by Age
    • 4.5.3. Diagnosed Incident Cases of Breast Cancer by Menopausal Status
    • 4.5.4. Diagnosed Incident Cases of Breast Cancer Segmented by Stage at Diagnosis
    • 4.5.5. Age-Standardized Diagnosed Incidence Rate of Breast Cancer
  • 4.6. Epidemiological Forecast for Breast Cancer (2013-2023) - Diagnosed Prevalent Cases
    • 4.6.1. Five-Year Diagnosed Prevalent Cases of Breast Cancer
    • 4.6.2. Five-Year Diagnosed Prevalent Cases by Menopausal Status
    • 4.6.3. Five-Year Diagnosed Prevalent Cases by Hormone Receptor Subtypes
  • 4.7. Discussion
    • 4.7.1. Epidemiological Forecast Insight
    • 4.7.2. Limitations of the Analysis
    • 4.7.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Treatment Overview
    • 5.1.1. Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB)
    • 5.1.2. Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIA)
    • 5.1.3. Treatment of Metastatic HER2-Positive Breast Cancer (Stage IV)
  • 5.2. US
    • 5.2.1. Diagnosis
    • 5.2.2. Clinical Practice
  • 5.3. France
    • 5.3.1. Diagnosis
    • 5.3.2. Clinical Practice
  • 5.4. Germany
    • 5.4.1. Diagnosis
    • 5.4.2. Clinical Practice
  • 5.5. Italy
    • 5.5.1. Diagnosis
    • 5.5.2. Clinical Practice
  • 5.6. Spain
    • 5.6.1. Diagnosis
    • 5.6.2. Clinical Practice
  • 5.7. UK
    • 5.7.1. Diagnosis
    • 5.7.2. Clinical Practice
  • 5.8. Japan
    • 5.8.1. Diagnosis
    • 5.8.2. Clinical Practice
  • 5.9. China
    • 5.9.1. Diagnosis
    • 5.9.2. Clinical Practice

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - HER2-Targeted Therapies
    • 6.2.1. Herceptin (trastuzumab)
    • 6.2.2. Tykerb (lapatinib)
    • 6.2.3. Perjeta (pertuzumab)
    • 6.2.4. Kadcyla (ado-trastuzumab emtansine, T-DM1)
  • 6.3. Product Profiles - General Targeted Therapies
    • 6.3.1. Afinitor (everolimus)
    • 6.3.2. Xeloda (capecitabine)
    • 6.3.3. Avastin (bevacizumab)
    • 6.3.4. Halaven (eribulin mesylate)
    • 6.3.5. Abraxane (nab-paclitaxel)
    • 6.3.6. Ixempra (ixabepilone)
  • 6.4. Hormonal Agents
    • 6.4.1. Tamoxifen
    • 6.4.2. Faslodex (fulvestrant)
    • 6.4.3. Aromatase Inhibitors

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. Brain Metastases
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Resistance to HER2-Targeting Therapies
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. Gilotrif (afatinib)
    • 8.2.2. Neratinib
  • 8.3. Promising Drugs in Early-Stage Development
    • 8.3.1. Palbociclib
    • 8.3.2. NeuVax (nelipepimut-S)
    • 8.3.3. Patritumab
    • 8.3.4. Ganetespib
    • 8.3.5. ARRY-380 (ONT-380)
    • 8.3.6. NVP-BYL719
  • 8.4. Biosimilars

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Roche/Genentech
    • 9.3.2. GlaxoSmithKline
    • 9.3.3. Boehringer Ingelheim
    • 9.3.4. Novartis
    • 9.3.5. Pfizer

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. United States
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. United Kingdom
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers
  • 10.9. China
    • 10.9.1. Forecast
    • 10.9.2. Key Events
    • 10.9.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed HER2-Positive Breast Cancer Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for this Report
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Therapy Area Director
    • 11.7.3. Epidemiologist
    • 11.7.4. Acting Director of Epidemiology
    • 11.7.5. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: AJCC Stage Definitions for Breast Cancer
  • Table 2: Prognosis for Breast Cancer in the US
  • Table 3: Selected Major Risk Factors and Comorbidities for Breast Cancer
  • Table 4: Breast Cancer Mortality Attributable to Lifestyle-Related Risk Factors
  • Table 5: 8MM, Current Status and Plans of Large-Scale Breast Cancer Screening Programs
  • Table 6: 8MM, Relative Survival Rate for Breast Cancer, All Ages*, Women, %, 1991-2004**
  • Table 7: Conversion of Common Staging Systems for Breast Cancer Used in the Forecast
  • Table 8: 8MM, Sources of the Breast Cancer Diagnosed Incidence Data Used in the Epidemiological Forecast
  • Table 9: 8MM, Diagnosed Incident Cases of Breast Cancer, Ages ≥20 Years, Women, N, 2013-2023
  • Table 10: 8MM, Diagnosed Incident Cases of Breast Cancer by Age, Women, N (Row %), 2013
  • Table 11: 8MM, Diagnosed Incident Cases of Breast Cancer by Menopausal Status, Ages ≥20 Years, Women, N (Row %), 2013
  • Table 12: 8MM, Diagnosed Incident Cases of Breast Cancer by Stage at Diagnosis, Ages ≥20 Years, Women, N, 2013
  • Table 13: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer, Ages ≥20 Years, Women, N, 2013-2023
  • Table 14: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer by Hormone Receptor Subtypes, Ages ≥20 Years, Women, N, 2013
  • Table 15: Treatment Guidelines for HER2-Positive Breast Cancer
  • Table 16: Product Profile - Herceptin
  • Table 17: Clinical Studies for Herceptin in the Adjuvant Setting
  • Table 18: Herceptin SWOT Analysis, 2013
  • Table 19: Global Sales Forecast ($m) for Herceptin, 2013-2023
  • Table 20: Product Profile - Tykerb
  • Table 21: Tykerb SWOT Analysis, 2013
  • Table 22: Global Sales Forecast ($m) for Tykerb, 2013-2023
  • Table 23: Product Profile - Perjeta
  • Table 24: Perjeta SWOT Analysis, 2013
  • Table 25: Global Sales Forecast ($m) for Perjeta, 2013-2023
  • Table 26: Product Profile - Kadcyla
  • Table 27: Kadcyla SWOT Analysis, 2013
  • Table 28: Global Sales Forecast ($m) for Kadcyla, 2013-2023
  • Table 29: Product Profile - Afinitor
  • Table 30: Afinitor SWOT Analysis, 2013
  • Table 31: Product Profile - Xeloda
  • Table 32: Xeloda SWOT Analysis, 2013
  • Table 33: Product Profile - Avastin
  • Table 34: Summary of Avastin Phase III Clinical Trials in Metastatic Breast Cancer
  • Table 35: Avastin SWOT Analysis, 2013
  • Table 36: Product Profile - Halaven
  • Table 37: Halaven SWOT Analysis, 2013
  • Table 38: Global Sales Forecast ($m) for Halaven, 2013-2023
  • Table 39: Product Profile - Abraxane
  • Table 40: Abraxane SWOT Analysis, 2013
  • Table 41: Global Sales Forecast ($m) for Abraxane, 2013-2023
  • Table 42: Product Profile - Ixempra
  • Table 43: Ixempra SWOT Analysis, 2013
  • Table 44: Global Sales Forecast ($m) for Ixempra, 2013-2023
  • Table 45: Summary of Minor Therapeutic Classes Used to Treat HER-2 positive breast cancer, 2013
  • Table 46: Unmet Need and Opportunity in HER2-Positive Breast Cancer
  • Table 47: Product Profile - Gilotrif
  • Table 48: Gilotrif SWOT Analysis, 2014
  • Table 49: Product Profile - Neratinib
  • Table 50: Neratinib SWOT Analysis, 2013
  • Table 51: Global Sales Forecast ($m) for Neratinib, 2013-2023
  • Table 52: Comparison of Therapeutic Classes in Development for HER2-Positive/HER2-Negative Breast Cancer, 2014
  • Table 53: HER2-Positive Breast Cancer - Early-Phase Pipeline, 2014
  • Table 54: Product Profile - Palbociclib
  • Table 55: Palbociclib SWOT Analysis, 2014
  • Table 56: Product Profile - NeuVax
  • Table 57: NeuVax SWOT Analysis, 2014
  • Table 58: Product Profile - Patritumab
  • Table 59: Patritumab SWOT Analysis, 2014
  • Table 60: Product Profile - Ganetespib
  • Table 61: Ganetespib SWOT Analysis, 2014
  • Table 62: Product Profile - ARRY-380
  • Table 63: ARRY-380 SWOT Analysis, 2014
  • Table 64: Product Profile - NVP-BYL719
  • Table 65: NVP-BYL719 SWOT Analysis, 2014
  • Table 66: Trastuzumab Biosimilars, 2014
  • Table 67: Key Companies in the HER2-Positive Breast Cancer Market in the 8MM, 2013-2023
  • Table 68: Roche's HER2-Positive Breast Cancer Portfolio Assessment, 2014
  • Table 69: Roche SWOT Analysis, 2014
  • Table 70: GSK's HER2-Positive Breast Cancer Portfolio Assessment, 2014
  • Table 71: GSK SWOT Analysis, 2014
  • Table 72: BI's HER2-Positive Breast Cancer Portfolio Assessment, 2014
  • Table 73: BI SWOT Analysis, 2014
  • Table 74: Novartis' HER2-Positive Breast Cancer Portfolio Assessment, 2014
  • Table 75: Novartis SWOT Analysis, 2014
  • Table 76: Pfizer's HER2-Positive Breast Cancer Portfolio Assessment, 2014
  • Table 77: Pfizer SWOT Analysis, 2014
  • Table 78: Global Sales Forecast ($m) for HER2-Positive Breast Cancer, 2013-2023
  • Table 79: Global HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023
  • Table 80: Sales Forecast ($m) for HER2-Positive Breast Cancer in the US, 2013-2023
  • Table 81: Key Events Impacting Sales for HER2-Positive Breast Cancer in the US, 2013-2023
  • Table 82: US HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023
  • Table 83: Sales Forecast ($m) for HER2-Positive Breast Cancer in France, 2013-2023
  • Table 84: Key Events Impacting Sales for HER2-Positive Breast Cancer in France, 2013-2023
  • Table 85: French HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023
  • Table 86: Sales Forecast ($m) for HER2-Positive Breast Cancer in Germany, 2013-2023
  • Table 87: Key Events Impacting Sales for HER2-Positive Breast Cancer in Germany, 2013-2023
  • Table 88: German HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023
  • Table 89: Sales Forecast ($m) for HER2-Positive Breast Cancer in Italy, 2013-2023
  • Table 90: Key Events Impacting Sales for HER2-Positive Breast Cancer in Italy, 2013-2023
  • Table 91: Italian HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023
  • Table 92: Sales Forecast ($m) for HER2-Positive Breast Cancer in Spain, 2013-2023
  • Table 93: Key Events Impacting Sales for HER2-Positive Breast Cancer in Spain, 2013-2023
  • Table 94: Spanish HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023
  • Table 95: Sales Forecast ($m) for HER2-Positive Breast Cancer in the UK, 2013-2023
  • Table 96: Key Events Impacting Sales for HER2-Positive Breast Cancer in the UK, 2013-2023
  • Table 97: UK HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023
  • Table 98: Sales Forecast ($m) for HER2-Positive Breast Cancer in Japan, 2013-2023
  • Table 99: Key Events Impacting Sales for HER2-Positive Breast Cancer in Japan, 2013-2023
  • Table 100: Japanese HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023
  • Table 101: Sales Forecast ($m) for HER2-Positive Breast Cancer in China, 2013-2023
  • Table 102: Key Events Impacting Sales for HER2-Positive Breast Cancer in China, 2013-2023
  • Table 103: Chinese HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023
  • Table 104: HER2-Positive Breast Cancer Incidence, 2013-2023
  • Table 105: HER2-Positive Breast Cancer Drugs, Key Launch Dates
  • Table 106: HER2-Positive Breast Cancer Drugs, Key Patent Expiries
  • Table 107: Average Body Weight and Surface Area Across the 8MM
  • Table 108: Average Annual Cost of Therapy ($) - Herceptin, Adjuvant
  • Table 109: Average Annual Cost of Therapy ($) - Subcutaneous Herceptin, Adjuvant
  • Table 110: Average Annual Cost of Therapy ($) - Perjeta, First Line
  • Table 111: Average Annual Cost of Therapy ($) - Tykerb, First Line
  • Table 112: Average Annual Cost of Therapy ($) - Kadcyla, Second Line
  • Table 113: Average Annual Cost of Therapy ($)- Halaven, Fourth Line
  • Table 114: Average Annual Cost of Therapy ($) - Abraxane, Fourth Line
  • Table 115: Average Annual Cost of therapy ($) - Ixempra, Fourth Line
  • Table 116: Average Annual Cost of Therapy ($) - Neratinib, Third Line
  • Table 117: Physicians Surveyed by Country

List of Figures

  • Figure 1: Basic Breast Anatomy, Including Key Lymph Nodes
  • Figure 2: 8MM, Age-Standardized Incidence Rate of Breast Cancer, Ages ≥15 Years, Women, Cases per 100,000 Population, 2008
  • Figure 3: 8MM, Incidence Rate of Breast Cancer, Ages ≥15 Years, Women, Rate per 100,000 Population, 2008
  • Figure 4: US, Incidence Rate of Breast Cancer, All Ages, Women, Cases per 100,000 Population, 1975-2009
  • Figure 5: 5EU, Incidence Rate of Breast Cancer, Ages ≥15 Years, Women, Cases per 100,000 Population, 1975-2010
  • Figure 6: Japan, Incidence Rate of Breast Cancer, All Ages, Women, Cases per 100,000 Population, 2003-2008
  • Figure 7: 8MM, Relative Survival Rate for Breast Cancer, All Ages*, Women, %, 1991-2004**
  • Figure 8: 8MM, Diagnosed Incident Cases of Breast Cancer, Ages ≥20 Years, Women, N, 2013-2023
  • Figure 9: 8MM, Diagnosed Incident Cases of Breast Cancer, by Age, Women, N, 2013
  • Figure 10: 8MM, Diagnosed Incident Cases of Breast Cancer by Menopausal Status, Ages ≥20 Years, Women, N, 2013
  • Figure 11: 8MM, Diagnosed Incident Cases of Breast Cancer by Stage at Diagnosis, Ages ≥20 Years, Women, N, 2013
  • Figure 12: 8MM, Age-Standardized Diagnosed Incidence Rate of Breast Cancer, Ages ≥20 Years, Women, Cases per 100,000 Population, 2013
  • Figure 13: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer, Ages ≥20 Years, Women, N, 2013-2023
  • Figure 14: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer by Menopausal Status, Ages ≥20 Years, Women, N, 2013
  • Figure 15: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer by Hormone Receptor Subtypes, Ages ≥20 Years, Women, N, 2013
  • Figure 16: Primary Completion Dates of Active Phase III Clinical Trials for Tykerb
  • Figure 17: Active Late-Stage Clinical Trials for Perjeta
  • Figure 18: Active Phase III Clinical Trials for Kadcyla
  • Figure 19: Active Phase III Clinical Trials for Afinitor
  • Figure 20: Clinical Trials for Halaven
  • Figure 21: HER2-Positive Breast Cancer - Phase II-III Pipeline, 2013
  • Figure 22: Gilotrif's Clinical Development in Breast Cancer
  • Figure 23: Clinical and Commercial Positioning of Gilotrif
  • Figure 24: Neratinib's Clinical Development
  • Figure 25: Clinical and Commercial Positioning of neratinib.
  • Figure 26: Global Sales ($m) of Branded Products for HER2-Positive Breast Cancer by Company, 2013-2023
  • Figure 27: Company Portfolio Gap Analysis in HER2-Positive Breast Cancer, 2013-2023
  • Figure 28: Global Sales for HER2-Positive Breast Cancer by Region, 2013-2023
  • Figure 29: Global Sales for HER2-Positive Breast Cancer by Drug Class, 2013-2023
  • Figure 30: Sales for HER2-Positive Breast Cancer in the US by Drug Class, 2013-2023
  • Figure 31: Sales for HER2-Positive Breast Cancer in France by Drug Class, 2013-2023
  • Figure 32: Sales for HER2-Positive Breast Cancer in Germany by Drug Class, 2013-2023
  • Figure 33: Sales for HER2-Positive Breast Cancer in Italy by Drug Class, 2013-2023
  • Figure 34: Sales for HER2-Positive Breast Cancer in Spain by Drug Class, 2013-2023
  • Figure 35: Sales for HER2-Positive Breast Cancer in the UK by Drug Class, 2013-2023
  • Figure 36: Sales for HER2-Positive Breast Cancer in Japan by Drug Class, 2013-2023
  • Figure 37: Sales for HER2-Positive Breast Cancer in China by Drug Class, 2013-2023
Back to Top